EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Deciphering Facioscapulohumeral Dystrophy in the clinical trials era: where are we now?

Francesca Torri, Beatrice Ciurli, Mariaconcetta Rende, Arianna Votta, Emanuele Mocciaro, Frida Karakashi, Matteo Lencioni, Elisabetta Ferraro, Massimiliano Filosto, Davide Gabellini, Gabriele Siciliano, Giulia Ricci

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology / edited by the Gaetano Conte Academy for the study of striated muscle diseases · 01.03.2025 · 44 (1) · 2-10

DOI: 10.36185/2532-1900-1047 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology / edited by the Gaetano Conte Academy for the study of striated muscle diseases, erschienen am 01.03.2025. Verfasst von Francesca Torri und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of New Technologies and Translational Research in Medicine and Surgery, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Muscular Dystrophy, Facioscapulohumeral. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Facioscapulohumeral muscular dystrophy (FSHD) is a common genetic disorder characterized by progressive muscle weakness, especially in the face, shoulders, and upper limbs. Despite extensive research, the underlying pathogenesis and clinical variability remain incompletely understood. This review aims to summarize recent advances in FSHD research, focusing on genetic and epigenetic factors and the potential for precision medicine.

Methods

A comprehensive review of recent literature was conducted, examining molecular mechanisms such as mutations in the D4Z4 region, DUX4 expression, RNA interference (RNAi) and antisense oligonucleotides (AOs). Clinical variability was analyzed to assess different disease phenotypes. Clinical trials investigating potential treatments, especially those targeting DUX4, were also reviewed.

Results

FSHD shows significant clinical variability, with different progression rates across phenotypes. The 4qA allele is linked to more typical forms of the disease, but epigenetic factors, including DNA methylation and miRNA expression, also influence disease severity. Despite progress, the exact molecular mechanisms driving disease expression remain unclear. Clinical trials, such as Losmapimod, show promise in slowing muscle degeneration, though results remain inconsistent.

Conclusions

FSHD presents significant challenges for therapy development due to its genetic complexity and clinical variability. Ongoing research is needed to clarify pathogenesis and identify reliable biomarkers. Future therapeutic strategies should focus on precision medicine, integrating genetic, clinical, and imaging data to optimize patient stratification and treatment efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, FacioscapulohumeralHumansClinical Trials as TopicEpigenesis, GeneticPhenotype

Stichwörter der Autor:innen

Clinical trialsClinical variabilityDUX4Facioscapulohumeral muscular dystrophy (FSHD)Therapeutic strategies

Autor:innen und Institutionen

  • Department of New Technologies and Translational Research in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Department of Biology, Unit of cell and Developmental Biology, University of Pisa, Pisa, Italy.
  • Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy.
  • UO Plastic Surgery, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
  • Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Zitieren

APA

Torri, F., Ciurli, B., Rende, M., Votta, A., Mocciaro, E., Karakashi, F., Lencioni, M., Ferraro, E., Filosto, M., Gabellini, D., Siciliano, G., & Ricci, G. (2025). Deciphering Facioscapulohumeral Dystrophy in the clinical trials era: where are we now?. Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology / edited by the Gaetano Conte Academy for the study of striated muscle diseases, 44(1), 2-10. https://doi.org/10.36185/2532-1900-1047

Vancouver

Torri F, Ciurli B, Rende M, Votta A, Mocciaro E, Karakashi F, et al. Deciphering Facioscapulohumeral Dystrophy in the clinical trials era: where are we now?. Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology / edited by the Gaetano Conte Academy for the study of striated muscle diseases. 2025;44(1):2-10. doi:10.36185/2532-1900-1047

BibTeX
@article{Torri2025,
  author = {Torri, Francesca and Ciurli, Beatrice and Rende, Mariaconcetta and Votta, Arianna and Mocciaro, Emanuele and Karakashi, Frida and Lencioni, Matteo and Ferraro, Elisabetta and Filosto, Massimiliano and Gabellini, Davide and Siciliano, Gabriele and Ricci, Giulia},
  title = {Deciphering Facioscapulohumeral Dystrophy in the clinical trials era: where are we now?},
  journal = {Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology / edited by the Gaetano Conte Academy for the study of striated muscle diseases},
  year = {2025},
  volume = {44},
  number = {1},
  pages = {2--10},
  doi = {10.36185/2532-1900-1047}
}
Kostenlos starten →